Anaerobic microbial macromolecules

Anaerobic microbial macromolecules, primarily deoxyribonucleic acid (DNA), serve as the collective therapeutic target for nitroimidazole antibiotics such as metronidazole and tinidazole (StatPearls, 2023). These targets are specific to anaerobic bacteria and certain protozoa because these organisms possess unique metabolic pathways, such as the pyruvate:ferredoxin oxidoreductase (PFOR) system, capable of reducing the drug's nitro group into highly reactive toxic intermediates (PubMed, PMID: 15888500). Once activated, these short-lived radicals interact with microbial DNA, causing a loss of helical structure, strand breakage, and the subsequent inhibition of nucleic acid synthesis (DrugBank, DB00916). This mechanism is bactericidal and protozoocidal, providing high selectivity because aerobic host cells lack the low-redox potential electron transport proteins required for drug activation (NIH, 2022). While DNA is the primary target, the reactive intermediates also damage other cellular macromolecules, including proteins and membranes, contributing to the rapid death of pathogens like Bacteroides fragilis, Clostridioides difficile, and Trichomonas vaginalis.

Other names

Microbial DNAAnaerobic bacterial DNAAnaerobic protozoal DNABacterial nucleic acidsMicrobial proteins

Reductive activation of the drug's nitro group by anaerobic metabolic enzymes (e.g., ferredoxin or flavodoxin) creates highly reactive nitroso free radicals that cause oxidative damage, covalent binding, and strand breakage of microbial DNA and other macromolecules.